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In this work, new efficient drug delivery systems based on cellulose nanofibers – titania nanocomposites 
grafted with three different types of model drugs such as Diclofenac sodium, Penicillamine-D and 
Phosphomycin were successfully synthesized and displayed distinctly different controlled long-term 
release profiles. Three different methods of medicine introduction were used to show that various 
interactions between TiO2 and drug molecule could be used to control the kinetics of long-term drug 
release. All synthesis reactions were carried out in aqueous media. Morphology, chemical structure and 
properties of the obtained materials were characterized by SEM, TEM and AFM microscopy, Nanoparticle 
Tracking analysis, X-ray diffraction, and TGA analysis. According to FT-IR and UV-Vis spectroscopy data, 
the titania binds to cellulose nanofibers via formation of ester bonds and to drug molecules via formation of 
surface complexes. The drug release kinetics was studied in vitro for Diclofenac sodium and Penicillamin-
D spectrophotometrically and for Phosphomycin using a radio-labeling analysis with 33P-marked ATP as a 
model phosphate-anchored biomolecule. The results demonstrated that the obtained nanocomposites 
could potentially be applied in transdermal drug delivery for anesthetics, analgesics and antibiotics. 
Introduction 
 Nanocomposites based on nanocellulose, nano- or microfibrilliar cellulose, cellulose nanofibers are new 
generation nanomaterials possessing wide range of practical applications in such domains as pharmacology1 
and medicine2, tissue engineering3-5, biosensors6, microfluidics elements7, materials for microencapsulation8 
and drug delivery9-12, as permoselective membranes13, and as a barrier to protect mucosal tissues14,15. The 
nanoscale cellulose possesses a whole complex of unique properties typical for nanomaterials in general, 
such as high specific surface area, enhanced chemical reactivity, high mechanical durability, together with 
biocompatibility, biodegradability, and non-toxicity, which make it an excellent candidate for drug release 
applications.  
 Due to these specific properties, bandage materials, transdermal patches, tablet binder, disintegrated 
vehicle for peptide and gene delivery can be obtained based on nanoscale cellulose, and raw materials for 
their production are almost unlimited16-18. In particular, nanocrystalline cellulose has been used as a matrix-
former material for long-lasting sustained drug delivery and for food packing materials19-22.  
 In recent years, the application of inorganic materials for bioencapsulation and controlled drug release 
has attracted considerable attention23,24. Particularly, nanosized titania, due to its unique photophysical and 
chemical properties, non-toxicity, and high biocompatibility, is a promising material and has great prospects 
for practical application in these fields. Generally, nanoporous titania is used as drug nanocarriers25,26. In a 
recent study, Li et al.27reported a novel drug controlled release system based on hybrid phosphonate–TiO2 
mesoporous nanoparticles as a scaffold, which was loaded with suitable drug molecules.  
 To the best of our knowledge, no attempts have been made in combining the advantageous 
characteristics of nanocrystalline celullose with the specific properties of nanosized titania by modification. 
This approach, however, has potential to open endless possibilities for creation of new efficient drug 
delivery systems with a whole range of functional properties. Previously, we obtained TiO2/cotton 
composites with high photocatalytic and antibacterial activity28,29. The aim of the present work was to 
develop potential application of the nanocomposites based on cellulose nanofibers and grafted titania as 
drug delivery system. 
 
Experimental 
 Copper sulfate (CuSO4·5H2O), sodium hydroxide (NaOH), ammonia (NH4OH, 25 wt%), sulfuric acid 
(H2SO4, 98 wt%), 1,2,3,4 – bytanetetracarboxylic acid (BTCA), sodium hypophosphite (NaH2PO2), 
Diclofenac sodium salt (C14H10Cl2NNaO2, Mw ~318.13), Penicillamine D ((CH3)2C(SH)CH(NH2)CO2H, 
Mw~149.21) Phosphomycin disodium salt (C3H5Na2O4P, Mw~182.02), polyvinyl alcohol (PVA, Mw 
146,000-186,000) were purchased from Sigma-Aldrich. The TiO2 nanosol was produced by CaptiGel AB, 
Uppsala, Sweden. Raw cotton (100%) was used as a starting material. 
Synthetic procedures 
Preparation of cellulose nanofibers 
 For obtaining cellulose nanofibers we have developed a method based on the use of copper ammonium 
complex for converting raw cotton (RC) into a molecular solution with subsequent regeneration by means 
of acid hydrolysis. 
 5 g of copper (II) sulfate were dissolved in 100 ml of distilled water, and then sodium hydroxide (5M) 
was added until precipitation (eq.1). The copper hydroxide precipitate was thoroughly washed by distilled 
water to remove Na+. Then, the precipitate was dissolved in 200 ml of ammonia (25 wt%) giving a deep 
blue solution of tetraamminediaquacopper dihydroxide (Schweitzer’s reagent) (eq.2). Two grams of raw 
cotton were added to the cuprammonium solution. When cotton was completely dissolved in the 
Schweitzer’s reagent (eq. 3), the solution was further used for obtaining aqueous suspension of cellulose 
nanofibers. 
CuSO4·5H2O+2NaOH=Cu(OH)2+ Na2SO4 + 5H2O (1) 
Cu(OH)2+4NH4OH= [Cu(NH3)4(H2O)2](OH)2+2H2O(2) 
2(C6H10O5)x+ 2x[Cu(NH3)4(H2O)2](OH)2=x[(C6H8O5)2Cu][Cu(NH3)4(H2O)2]+4xNH3+ 4xH2O(3) 
For this purpose, 25 ml of Schweitzer’s reagent solution, containing the dissolved cotton, was added into 
140 ml of the sulfuric acid solution (40 wt%) and stirred vigorously at 60 ºC for 4 hours. After that, 
hydrolysis was immediately quenched by adding 500 ml of cold distilled water to the reaction mixture. The 
sulfuric acid was removed from the resulting suspension by centrifuging with distilled water until pH=6. 
x[(C6H8O5)2Cu][Cu(NH3)4(H2O)2] + 4xH2SO4= 2(C6H10O5)x+ CuSO4+(NH4)2SO4(4) 
Preparation of nanocomposites loaded with different drugs 
 Firstly, to cross-link titania nanoparticles with cellulose nanofibers, 1,2,3,4-butanetetracarboxylic acid 
was used as a spacer in the presence of sodium hypophosphite (SHP). For this, the obtained aqueous 
suspensions of cellulose nanofibers were treated by BTCA (0,002 mol) with SHP (0,002 mol) aqueous 
solution at 70ºC during 2 h. Next, titania nanosol was added to the obtained solution and the modification 
was carried out at 70ºC during 2 h. The obtained nanocomposites were dried at 40°С for 48 h. 
Introduction of drugs 
 The BTCA-treated cellulose nanofibers were modified by TiO2 nanosol and drug by using three different 
methods. 
 Method #1 (M1): drug powder (Diclofenac sodium salt - DS, Penicillamine D - PCA-D or 
Phosphomycin disodium salt - Phos) was initially dissolved in titania nanosol and thereafter the obtained 
solution was added to an aqueous suspension of cellulose nanofibers and kept at 70ºC during 2 h. The 
obtained nanocomposites were dried at 40°С for 48 h. 
 Method #2 (M2): The drug powder (DS, PCA-D or Phos) was initially dissolved in water and then 
added together with the titania nanosol simultaneously to an aqueous suspension of cellulose nanofibers. 
The mixture was kept at 70 ºC during 2 h. The obtained nanocomposites were dried at 40°С for 48 h.  
 Method #3 (M3): firstly, TiO2 nanosol was added to an aqueous suspension of cellulose nanofibers and 
kept at 70ºC during 2 h. Then, an already dissolved drug powder (DS, PCA-D or Phos) in water was added 
to the solution and kept at 70 ºC during 2 h. The obtained nanocomposites were dried at 40°С for 48 h. The 
composition of the obtained samples and the method of drug modification are presented in the Table 1. In 
order to obtain nanocomposites as a film, 3% of PVA was used. 
Structure characterization 
 Scanning and transmission electron microscopy images of the samples were obtained using Carl Zeiss 
NVision. The elemental analysis of pure cellulose nanofibers and nanocomposites was carried out by a 
HITACHI TM-1000 scanning electron microscope equipped with an EDX detector. For analysis a drop of 
each of the diluted suspensions was deposited in the holder with a carbon pad and allowed to dry.  
 Atomic force microscope (AFM) studies were carried out using a Bruker MultiMode 8 microscope. Pure 
cellulose nanofibers (PCNF) and nanocomposite based on cellulose nanofibers modified with TiO2 
(CNF_TiO2) were applied on carbon pad having clean surface. 
 For the aqueous suspensions of PCNF and CNF_TiO2 samples, nanoparticle tracking analysis 
measurements based on Brownian motion of nanoparticles were carried out using a NanoSight instrument, 
permitting to determine the hydrodynamic size and particle size distribution in real time.  
 IR spectra of all samples were obtained with a Perkin Elmer FT-IR spectrometer Spectrum-100. A total 
of 8 scans were carried out on wavenumbers from 400 cm-1 to 4000 cm-1, in transmittance mode. All spectra 
were smoothed and baseline corrected. 
 Thermo-gravimetric analysis was carried out in air at a heating rate of 10 ºC/min, using a Perkin-Elmer 
TGA-7 or Pyris 1 device. 
 The X-ray powder diffraction (XRD) studies were carried out at room temperature using a Bruker APEX 
II CCD diffractometer (Mo Kα 0,71, graphite-monochromator). The main diffraction peak was integrated 
and used to calculate the crystalline index (CrI,%) of the samples: 
CrI(%)=(Itotal-Iam)/Itotal× 100 
where Itotal is the scattered intensity at the main peak of cellulose I or II, and Iam is the scattered intensity due 
to the amorphous portion evaluated as the minimum intensity between the main and secondary peaks. 
Radiological studies of model drug adsorption 
 The measurements of uptake and release from pure cellulose nanofibers and nanocomposite based on 
titania and cellulose nanofibers were performed by Ridgeview Instrument AB, exploiting Ligand TracerTM 
White technology, using 33P-labeled (ATP) (adenosine 5''-triphosphate, substitution on γ-phosphorus atom, 
1 ml of solution with 1mCurie total β-activity)as model compound30,31. A part of sample was deposited on a 
PMMA Petri dish as dispersion in toluene and immobilized by drying in air. Association solution (3.33 ml 
of MQ with 0.1% Tween 20) was added to the dish that was mounted in an inclined position into the 
instrument and  subjected to rotation so that the immobilized material was periodically wet by solution and 
its β-emission was registered immediately afterwards. 1μl of 33P-marked ATP solution (resulting in 1nM of 
33P-ATP in the dish) was added after 40 min and one more portion of  2 μl of 33P-marked ATP solution of 
33P-marked ATP solution (resulting in ~ 3 nM of 33P-ATP in the dish) – after 23 hours, corresponding to the 
start of saturation in the observed adsorption. When the adsorption equilibrium was achieved (after 43 
hours), the mother liquor was replaced by the dissociation solution (phosphate buffer solution (pH 7.4) with 
0.1% Tween 20), and the decrease in radioactivity in the material was followed in the same way. 
 
In vitro drug release 
 The in vitro release studies of Diclodenac Sodium were carried out by placing the nanocomposites 
containing TiO2 and DS in definite volume (300 ml) of releasing medium (10-fold isotonic NaCl solution) 
at constant temperature (37±0.5°C) on constant stirring at 100 rpm32. To investigate the release profile of 
Penicillamine D, the nanocomposites containing TiO2 and PCA-D were incubated in 300 ml of citrate 
buffer at constant temperature (37±0.5°C) on constant stirring at 100 rpm33. At determined time intervals, 1 
mL of each solution was taken out for analysis, and the same volume of fresh medium was added to 
maintain a constant volume. Diclofenac and Penicillamine D content in each aliquot was determined by 
spectrophotometry. All the experiments were made three times to get an indication about the 
reproducibility. UV–Vis quantitative analysis of drugs was performed on a UV/Vis spectrophotometer UV-
1800. A linear calibration curve for DS and PCA-D was obtained at 278 nm and 270 nm, respectively. 
Released drug was determined by using the following equation: 
Drug release (%) = (released drug)/(total drug)×100 
where released drug was calculated from the drug concentration measured in the total volume and total drug 
was the amount loaded in the obtained sample. 
Results and discussion 
I. Characterization of pure cellulose nanofibers and the nanocomposite based on cellulose nanofibers 
modified with TiO2 
 The surface morphology and size distribution of pure cellulose nanofibers and obtained nanocomposites 
based on cellulose nanofibers and titania were analyzed by atomic force microscopy, transmission and 
scanning electronic microscopes together with detailed EDX analysis of representative samples. Fig.1 (a,b) 
displays the SEM images of the PCNF sample surface. It could be noted (see Fig.1(a)) that the surface of 
pure cellulose nanofibers exhibited smooth, homogeneous structures and didn’t contain any contaminations, 
as confirmed by the EDX. Figure 1 shows also the TEM images of PCNF (b) and  CNF_TiO2(d). Pure 
cellulose nanofibers have a rod shape, and their rough average length and diameter were about 15 and 5 nm, 
respectively. The surface morphology for CNF_TiO2 sample is considerably different from that of pure 
cellulose nanofibers (Fig.1c,d). After TiO2 modification, the CNF_TiO2 sample has uniform morphology 
and contains TiO2 nanoparticles evenly distributed over the whole surface. Fig 1(d) also shows quantitative 
EDX analysis for the CNF_TiO2 sample confirming the presence of titanium dioxide. NTA analysis showed 
particle size distribution of PCNF and CNF_TiO2 samples centred at around 260 nm and 160 nm 
respectively for the hydrodynamic size, involving also water in primary hydration layers (Fig.1). The larger 
hydrodynamic size for pure cellulose nanofibers in comparison with those in CNF_TiO2 sample is 
connected with their aggregation via strong hydrogen bonding, which is apparently decreased after their 
coating by titania. High resolution AFM images of PCNF and CNF_TiO2 samples are presented in Fig.2. 
The obtained results also confirmed that pure cellulose nanofibers had homogeneous topography (Fig.2a). 
CNF_TiO2 sample was uniformly coated by titania nanoparticle with a size of around 10 nm (Fig.2 (b,c)). 
Thus, the use of CaptiGel nanosol allows to deposit uniform single layer of TiO2-coalesced nanoparticles 
onto the surface of cellulose nanofibers.  
 According to the XRD analysis of PCNF and CNF_TiO2 (Fig.3) the starting cellulosic material displayed 
a typical X-ray diffraction pattern of native cellulose-I with characteristic stronger diffraction peaks at 2θ = 
7,1° and 10,4° and a weaker peak as a shoulder at 2θ = 9,3° which refers to cellulose-II apparently present 
in this case. This is evidenced by the presence of clear diffraction peaks at 2θ = 5,7°(101) and 2θ = 9,3° 
(101�), see Tab.2. The absence of the TiO2 diffraction peaks in the sample CNF_TiO2 should be remarked, 
as it shows that the size of TiO2 nanoparticles is smaller than the coherence domain required for the X-ray 
reflection. Crystallinity index was also calculated to reveal the differences between the raw cotton and the 
synthesized materials (Tab. 2). XRD results showed an increase in the crystallinity degree of the prepared 
samples via the acid hydrolysis in comparison with the RC sample. For raw cotton the crystalline index was 
66.9%. Acid hydrolysis for the production of nanocrystalline cellulose improved the crystallinity index to 
86%. Obviously, the increase in crystallinity originates from the removing of amorphous parts from 
cellulose composition during the acid hydrolysis. It is also associated with cellulose recrystallization, which 
results in its conversion to highly ordered state due to redistribution of the hydrogen bonds. 
 An insight into interaction of BTCA with titania nanoparticles on the surface of cellulose nanofibers is 
provided by the FTIR spectroscopy (see Fig.4). The main absorption bands for PCNF and CNF_TiO2 
samples are presented in Table TS1 (please, see supplementary). On a qualitative level, the obtained IR-
spectra are quite similar, the majority of absorption peaks practically coincide. It indicates a “soft” 
modification process wherein the supramolecular structure of nanocrystalline cellulose remains unchanged. 
The broad band at 3600-3000 cm–1 is observed in all synthesized samples and refers to the stretching 
vibrations of the hydroxyl groups involved in intermolecular hydrogen bonds. 
 The stretching vibrations of the СH- and CH2-bonds of methylene and methine cellulose groups are in 
2980-2830 cm–1 region. The absorption peak at 1642 сm–1 indicates water presence. The absorption peak at 
1159 cm–1 is attributed to C–O–C asymmetric stretching vibrations. However, several characteristic 
absorption bands show differences in the chemical structure of the obtained samples. We confirmed earlier 
that TiO2 nanoparticles are cross-linked to the surface of a cotton fiber by formation of transverse ester 
bonds with the cross-linking agent 1,2,3,4 – butanetetracarboxylic acid (see Scheme 1).29 So, the absorption 
peaks are assigned to carboxylic groups in CNF_TiO2 sample after TiO2 modification with the usage of the 
cross-linking agent BTCA in the 1800–1600 cm–1 region. The carbonyl adsorption peak at 1710 cm–1 is 
attributed to C=O stretching and confirmed the formation of ester bonds in the CNF_TiO2 sample. The 
weak absorption peaks at 835 сm–1 and 815 сm–1 are attributed to Ti-O-Ti vibration (Fig.4b). The 
absorption band at 1420 cm–1 characterizes the crystallinity, whereas the absorption band at 894 cm–1 
indicates the amorphous component of the samples. Thus, as a result of chemical modification of the 
synthesized nanocrystalline cellulose by TiO2 nanoparticles, a decrease of the amorphous band is observed 
at 894 cm–1, which confirms the increase in crystallinity degree in the CNF_TiO2 sample.  
 Thermal stability and thermal decomposition for the raw cotton, PCNF and CNF_TiO2 samples were 
investigated by thermogravimetric analysis and presented in Fig. FS1 (please, see supplementary). All 
samples showed a three-step weight loss. Firstly, raw cotton and PCNF together with CNF_TiO2 samples 
had a small weight loss at low temperature range (less than 230ºC), corresponding to the evaporation of 
adsorbed water. The main mass loss stage of RC, PCNF and CNF_TiO2 samples ranged from 276ºC to 
360ºC, with maximum thermal degradation temperature at 360ºC, 348ºC and 337ºC, respectively. In case of 
cellulose nanofibers modified with TiO2, the reason of the shift to low temperature of 337ºC can be 
assigned to the removal of residual organics from titania. As it can been seen in Fig. FS1, the thermal 
stability of pure cellulose nanofibers with and without TiO2 was higher than that of the raw cotton. It can be 
attributed to removal of hemicelluloses and lignin using acid hydrolysis route. Moreover, thermal stability 
and heat resistance also have a close relationship with the crystallinity degree. In particular, crystalline 
regions in cellulose are much more stable than amorphous parts in cellulose34-36. Therefore, increase of 
crystallinity degree during chemical treatment also improved the heat resistance of PCNF and CNF_TiO2 
samples. 
 For original cotton, the maximum thermal degradation occurred at 494ºC with a maximum weight loss 
of 99.2%. PCNF and CNF_TiO2 samples showed a maximum thermal degradation temperature at 550ºC 
and 548ºC, respectively. In comparison to PCNF sample, the maximum weight loss of CNF_TiO2 samples 
decreases by addition of titania nanoparticles and the total amount of TiO2 is 10wt% in the obtained 
nanocomposites 
 
II. Preparation and characterization of nanocomposite TiO2-nanocellulose loaded with different 
drugs  
 
 Three different medicines, Diclofenac sodium, Penicillamine-D and Phosphomycin, were chosen as 
model drugs for modification of cellulose nanofibers and further investigation of resulting drug release 
system. These drugs can easily be quantified in complex systems using different methods, including 
spectrophotometry37, chromatography38 and SEM analysis. Diclofenac sodium is a potent non-steroidal 
compound with pronounced analgesic, anti-inflammatory and antipyretic properties. Currently, DS is used 
in surgery, traumatology and sports medicine, soft-tissue lesions etc. Penicillamine D (2-amino-3-mercapto-
3-methylbutanoic acid) is derived from hydrolytic degradation of penicillin antibiotics and contains −SH, 
−NH2 and –COOH groups. PCA-D is used as a medicinal agent against rheumatoid arthritis, and other 
chronic autoimmune diseases39. Phosphomycin [(2R,3S-3-methyloxiran-2-yl) phosphonic acid] is a natural 
broad spectrum  antibiotic compound which is mainly used for the treatment of uncomplicated urinary tract 
infections and meningitis, pneumonia, and pyelonephritis40. 
 Noteworthy, different studies generally reported the use of titania nanoparticles for coating cellulose 
fibers for photocatalytic and antibacterial application41-44. In this study, we developed a new approach using 
TiO2 as active ingredient for drug delivery. The purpose of chemical modification was to synthesize a novel 
transdermal drug delivery system bonding a drug molecule to the biopolymer through interaction with TiO2 
grafted onto it (Scheme 2). The drug grafting was performed in amounts calculated in assumption of the 
formation of a uniform, single layer coverage on TiO2-modified cellulose nanofibers’ surface46 (See 
supplementary material for explanation). Thus, total amounts of Diclofenac Sodium, Penicillamine D and 
Phosphomycin in the obtained nanocomposites were 7.7wt%, 3.8wt% and 4.7wt%, respectively. The visual 
optical images of the nanocomposite based on cellulose nanofibers and TiO2 with different type of drugs 
such as Diclofenac Sodium, Penicillamine D and Phoshomycin, possessing high optical transparency, are 
presented in Fig. FS2 (please, see supplementary).  
 Drug modification of nanocomposite was performed by three different methods, which are described in 
the experimental part and named M1, M2, and M3. The first method (M1) was based on initial dissolution 
of drug powder in titania nanosol, followed by addition of the obtained solution to aqueous solution of the 
cellulose nanofibers. In the second case (M2), the drug powder was first dissolved in water and then added 
simultaneously with the titania nanosol to aqueous solution of the cellulose nanofibers. In the third method 
(M3), the titania nanosol and drug was added to aqueous suspension of the cellulose nanofibers 
sequentially. For instance, M1 and M2 were chosen for Diclofenac Sodium and SEM images confirmed the 
homogeneous distribution of drug (Fig.5(a,b)). On the contrary, M3 showed not to be suitable for DS since 
it agglomerates onto the cellulose nanofibers surface and does not interact with it, crystallizing as a separate 
phase as observed in Fig. FS3 (please, see supplementary). The availability of drugs in nanocomposite was 
evaluated by EDS analysis and also presented in Fig. FS3. In order to obtain uniform distribution of the 
drug within the cellulose nanofibers film and to bond drugs to cellulose nanofibers, the methods M1, M3 
and M2, M3 were chosen for Penicillamine D and Phoshomycin, respectively. In case of using 
Penicillamine D, SEM images of CNF_TiO2_PCA-D_M1 and CNF_TiO2_PCA-D_M2 samples showed 
that PCA-D bonding with TiO2 was strongly incorporated into the surface of biopolymer matrix 
(Fig.5(c,d)). EDX quantitative analysis for these samples confirmed the presence of titanium dioxide and 
PCA-D on the samples (Fig.5(3,4)). According to SEM images of the nanocomposites modified with TiO2 
and Phoshomycin, the usage of method #2 and #3 produced a smooth and homogeneous surface with good 
distribution of a drug (Fig.5(e,f)). 
 In order to investigate possible interaction between nanocomposite and various drugs, IR- and UV-Vis 
spectroscopies were used. According to the obtained data from IR-spectroscopy, no new absorption peaks 
after drug modifications were observed for any of the synthesised nanocomposites. Absence of the 
characteristic peaks can be attributed to the fact that sensitivity of infrared spectroscopy does not identify 
such small amount of the immobilized drug. Consequently, drug molecule and nanocomposite are 
compatible with each other. It is important to mention that strong chemical interaction between these 
components may lead to complete loss of medical properties of drugs45. At the same time, there is 
possibility of intermolecular interactions since the drug molecule contains various functional groups. 
Previously, we reported the production of a heteroligand complex between Penicillamine D as a modifying 
ligand and titanium alkoxide via chemisorption mechanism, involving surface chelation32. To detect the 
complexation of TiO2 and the two model drugs, Diclofenac Sodium and Penicillamine D, UV-Vis 
spectroscopy was used. For this purpose, drug powder of DS or PCA-D was dissolved in titania nanosol. 
The intensity of maximum absorption peak at 224 nm was observed for pure titania nanoparticles and used 
as a reference32. The spectrum of the resulting solution from reaction between titania nanosol and 
Diclofenac sodium shows an absorption peak at 375 nm (Fig.6a). In the case of Penicillamine D, the 
absorption peak was centered at 474 nm (Fig.6b). These results confirmed the complexation of drugs on the 
surface of titania. Thus, titania binds to cellulose nanofibers via formation of ester bonds and with drug 
molecules due to formation of chelating complexes. The modification by different types of drugs resulted in 
changes to the crystalline properties of the nanocomposites. Fig.7 shows the typical X-ray diffractograms of 
cellulose type II with characteristics peaks at 2θ = 5.5º and 9.4º. The results in Table II clearly demonstrate 
an increase in the crystallinity degree of more than 10% after modification of drugs in comparison with pure 
cellulose nanofibers. 
 
Radio-labeling analysis of 33P-ATP interaction 
 
 The goal of this work was to develop nanocomposites as drug delivery system namely as a transdermal 
patches for skin application. To study the in vitro kinetics of Phosphomycin release from nanocomposite 
based on cellulose nanofibers and TiO2, we performed radio-labeling analysis using phosphorylated drug 
33P-marked ATP as a model of Phosphomycin. Technique and examples of possible applications of this 
method can be found in the literature46-48. As it can be seen from Fig.8(a), no uptake is observed for the 
CNF sample. The uptake and release of 33P-marked ATP from CNF_TiO2 sample in comparison with the 
pure cellulose nanofibers are presented in Fig.8b. Two different concentrations of 33P-marked ATP, 1 nM 
and 3 nM were measured. Firstly, 3 ml of Milli-Q-pore water with 0.1 % Tween 20 was added with 40 min 
measurement of baseline to the dish with CNF and CNF_TiO2 samples. Then, 1μl of 1 nM 33P-marked ATP 
was added with 23 h of association measurement. After that, another 2 μl of 33P-ATP was added, resulting 
in 3 nM 33P-ATP in the dish with the samples for further association measurement for 21.5 h. Finally, the 
liquid was replaced with 3 ml of phosphate-buffered saline (PBS) and 0,1 % Tween 20 for release 
measurement. Previously, we reported studies of immobilization and release of 33P-marked ATP from 
mesoporous titania microparticles31. The obtained data demonstrate great affinity of material to 
phosphorylated ligands with a slow release of 20% of 33P-ATP in 200 h from these titania microparticles, 
which allows the application of titania microparticles as smart drug release sources. In this work, we used 
titania nanoparticles for cellulose nanofibers modification. Strong binding of 33P- marked ATP with the 
surface of CNF_TiO2 sample was also observed, as in pure titania microparticles31 (Fig.8b). In particular, 
33P-marked ATP 1nM associated and reached the equilibrium with the sample in 10 h and in more than 21.5 
h for 3nM 33P-ATP. It should be mentioned that surface saturation was not achieved with high 
concentration. The release of 33P-marked ATP from CNF_TiO2 sample occurred in two steps: firstly, 40% 
of 33P-marked ATP dissociated after first 4 h and only an additional 25% dissociated in the following 100 h. 
Thus, the synthesized nanocomposites based on cellulose nanofibers and TiO2 are very promising material 
for drug delivery application possessing very slow releasing properties. 
 
In vitro drug release  
 
 According to earlier reports in literature, the release of various drug molecules from nanocrystalline 
cellulose and derived composites was quite rapid49-51.In this work, two different methods of drug 
modification were used to show that various interactions between TiO2 and drug molecule could be used to 
control the kinetic of long-term drug release. Firstly, to determine the TiO2 stability in nanocompostites, we 
investigated in vitro release of titania from CNF_TiO2 sample. As it can be seen from the Fig. FS4, only 
negligible amount of titania was released from nanocomposites in 3 days. One possible reason for low 
release of TiO2 may be the strong bonding between titania nanoparticles and cellulose nanofibers achieved 
via grafting. Fig.9 shows the release curves of Diclofenac Sodium and Penicillamine D from the 
nanocomposites obtained by method #1 and #2. The release mechanisms for each drugs incorporated into 
nanocomposite by two different methods are mostly similar and the release curve can be considered as an 
isotherm with saturation. Comparison between release profiles of both drugs from nanocomposite showed 
that DS is released much faster than PCA-D regardless of the modification method. According to obtained 
results, for CNF_TiO2_DS_M1 sample, the release of DS is carried out with a constant speed for more than 
10 hours, reaching the equilibrium in 16 hours with a total amount of DS released around 50% (Fig.9a). A 
similar behaviour of slow DS release was observed for CNF_TiO2_DS_M2 sample, but only 28% of DS 
was released over 15 h (Fig.9b). The nanocomposites with Penicillamine D obtained by method #1 and #2 
released the drug more slowly. The in vitro release profiles of PCA-D from CNF_TiO2_PCA-D_M1 and 
CNF_TiO2_PCA-D_M2 samples are shown in Fig.9(c,d). As can be seen from Fig.9(c), CNF_TiO2_PCA-
D_M1 sample displayed a sustained long-term release profile of Penicillamine D where around 31% of drug 
released in a controlled manner over 96 hours. Method #2 for incorporation of PCA-D into the 
nanocomposite allows reduction of the release time to 43 hours with a total amount of ~40% (Fig.9d).  
Thus, these studies clearly demonstrate that using different methods of binding drug molecule to the 
biopolymer through interaction with TiO2 provide slow release, and most importantly, the level of released 
drug remains constant over a long time. The observed difference between release times of DS and PCA-D 
can be also explained by different solubility of drugs in water52,53. Specifically, the solubility of Diclofenac 
sodium54 at 25 ºC is 50 mg/ml, which is higher than that of Penicillamine D (30 mg/ml). So, swollen 
nanocomposites contain a large amount of water and diffusion process of a drug can proceed faster and 
easier than in case with PCA-D. It is important to note that using cross-linking agent for binding TiO2 with 
cellulose nanofibers has important implications for the release process. In particular, burst drug release 
profile was observed for nanocomposite based on cellulose nanofibers and TiO2 with DS prepared by 
method #1 and #2 without usage of cross-linking agent (Fig.10). The obtained results showed that 93% and 
81% of the entrapped DS was completely released within 10 min from nanocomposite with DS obtained by 
method #1 and #2 without using BTCA to cross-link titania with cellulose nanofibers, respectively. Similar 
results have been reported by N. Silva et al55. They investigated the potential application of bacterial 
cellulose membranes as a transdermal delivery system for the delivery of Diclofenac. In fact, about 90% of 
the total drug was released after 10 min. Apparently, the drug was lost together with the non-grafted titania 
simply washed from the material to which in the absence of the cross-linking agent it was not chemically 
bound. So, it can clearly be observed that application of cross-linking agent is not superfluous but necessary 
because the cellulose nanofibers modified only with titania and drug lose their drug delivery properties.  
 In perfect agreement with the main goal of this study, the nanocomposites based on cellulose nanofibers 
and TiO2 modifying with three types of drug were successfully produced for dermal application with a 
completely controlled drug release. Depending on required therapeutic effect and period of healing, 
different type of nanocomposites with immobilized drug can be applied to treat diseases. In case of 
Diclofenac Sodium, relatively rapid onset of analgesic and anti-inflammatory effects is required. On 
contrary, the use of anti-inflammatory agents such as Penicillamine D and antibiotics such as 
Phosphomycin requires long-term treatment. Thus, the obtained results of release kinetics are in a good 
agreement with the medicinal properties of drugs. Namely, depending on speed, drug release from 
nanocomposite based was in the following order: Diclofenac Sodium > Penicillamine D > Phosphomycin.  
 Thus, the obtained nanocomposites can give possibility to generate a new smart drug delivery patch with 
a whole complex of therapeutic properties. In vitro effects of a series of antibiotics incorporated into the 
produced slow release matrix has been investigated and will be reported separately in the near future. 
The drug delivery matrices reported in the present work are employing nano titania as active component for 
the drug binding and retention. While TiO2 is certified as both food additive (E171 in EU) and as solar 
protection factor in skin applications (FDA approved concentration in sunscreen formulations up to 25 
wt%)56 and is often used as negative control in the toxicity studies for nanoparticle materials,57 there are still 
some concerns about its potential health effects.58 The impact of nano titania on human health is strongly 
dependent on the size and crystallinity of the particles and the way of exposure, the introduction into the 
lungs through aspiration being regarded as most hazardous. The composite material in the present study is 
containing titania strongly bound to the matrix, so the loss into air should be considered as negligible. In the 
form of small nanoparticles, the titania is known to be highly bio-digestible,59 transforming in biological 
fluids (containing normally appreciable concentrations of chelating carboxylate ligands such as citrate and 
lactate) into soluble and non-toxic carboxylato-titanate species.31,32,59  
 
Conclusions 
 
 In this work, we successfully synthesized a new type of nanocomposites based on cellulose nanofibers 
and modifying TiO2 with three types of medicines, namely, Diclofenac sodium, Penicillamine-D and 
Phosphomycin. Experiments confirmed that drugs are uniformly distributed within the cellulose nanofiber 
film. One of the most important advantages of this work is the use of titania as a binding agent between 
cellulose nanofibers and a drug molecule, which provides a slow and controlled release. The drug release 
studies showed long-term release profiles with different kinetics of release depending on the medicine used. 
The quickest release was observed for the more soluble painkiller, slower one for the anti-inflammatory 
agent and the longest release took place for the strongly chemisorbed antibiotic agent. Thus, the 
nanocomposites produced by this technology can potentially be applied to transdermal drug delivery 
patches, as anesthetics, analgesics and wound-dressing materials. 
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Table 1 Composition of the samples 
Sample BTCA (mol) 
SHP 
( mol ) 
TiO2 
(mol) 
Drug 
(mol) 
Method of 
modification 
CNF_TiO2 0,002 0,002 1,5·10-4 - - 
CNF_TiO2_DS_M1 0,002 0,002 1,5·10-4 4,74·10-5 Method #1  
CNF_TiO2_DS_M2 0,002 0,002 1,5·10-4 4,74·10-5 Method #2 
CNF_TiO2_ PCA-D_M1 0,002 0,002 1,5·10-4 4,74·10-5 Method #1 
CNF_TiO2_PCA-D_M2 0,002 0,002 1,5·10-4 4,74·10-5 Method #2 
CNF_TiO2_Phos_M2 0,002 0,002 1,5·10-4 4,74·10-5 Method #2 
CNF_TiO2_Phos_M3 0,002 0,002 1,5·10-4 4,74·10-5 Method #3 
 
Table2 X-ray diffraction results  
Sample 
Peak position (2θ) Crystalline 
index 
(CrI, %) 
(101) (110) (101�) 200 
Cell-II Cell-I Cell-II Cell-I 
RC - 7.1 9.3 10.4 66.9 
PCNF 5.7 - 9.3 - 86.2 
CNF_TiO2 5.8 - 9.2 10.4 86.2 
CNF_ TiO2_ DS_M1 5.7 - 9.2 - 97.9 
CNF_ TiO2_DS_M2 5.5 - 9.3 - 98.1 
CNF_TiO2_PCA-D_M1 5.5 - 9.3 - 97.0 
CNF_TiO2_PCA-D_M2 5.5 - 9.2 - 97.3 
CNF_TiO2_Phos_M2 5.6 - 9.3 - 96.0 
CNF_TiO2_Phos_M3 5.4 - 9.4 - 95.7 
 
 Scheme 1 Proposed mechanism of interaction of pure cellulose nanofibers with BTCA and TiO2 
 
 
Scheme 2 Proposed scheme for the interaction of nanocomposite based on cellulose nanofibers and TiO2 with 
different types of drugs 
 
 
 
 
 
Figure.1 SEM and TEM images of (a,b) PCNF and (c,d) CNF_TiO2 respectively together with the hydrodynamic 
size of pure cellulose nanofibers and nanocomposite based on cellulose nanofibers modified with TiO2 
 
Figure.2 AFM images of (a) PCNF and CNF_TiO2 samples (b,c) 
 
 
 
 
 
Figure.3 X-ray diffraction patterns of (a) RC; (b) PCNF and (c) CNF_TiO2 
 
 
Figure.4 FTIR spectra of (a) PCNF and (b) CNF_TiO2 
 
 
Figure.5 SEM micrographs and EDX analysis of the samples: (a,1) CNF_TiO2_DS_M1, (b,2) CNF_TiO2_DS_M2, 
(c,3) CNF_TiO2_PCA-D_M1, (d,4) CNF_TiO2_PCA-D_M2, (e,5) CNF_TiO2_Phos_M2, (f,6) 
CNF_TiO2_Phos_M3 
 
 
Figure.6 UV spectrum of the resulting solution from reaction between titania and Diclofenac sodium (a); between 
titania and Penicillamine D (b) 
 
 
Figure.7 X-ray diffraction of the nanocomposites based on cellulose nanofibers modifying with TiO2 and different 
drugs 
 
 
Figure.8 Real-time binding and release curve of 1 nM and 3 nM33P-marked ATP to (a) CNF and (b) CNF_TiO2 
sample 
   
 
Figure.9 In vitro drug release profiles from the obtained nanocomposites: (a) CNF_TiO2_DS_M1, (b) 
CNF_TiO2_DS_M2, (c) CNF_TiO2_PCA-D_M1, (d) CNF_TiO2_PCA-D_M2 
 
Figure.10 In vitro diclofenac sodium release profile from the nanocomposites based on cellulose nanofibers and 
TiO2 with DS obtained by method #1 (b) and #2 (a) without using cross-linking agent.  
 
 
 
 
 
 
